hotspot -WSS

hotspot

author：hotspot 2025-10-02 17:22:44 - browse：35

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT Virtual Event: How to Increase Diversity in Clinical Trials

WSS

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Paxlovid should be available without a positive Covid test

After a drawn out lobbying fight, ARPA

Why do we get seasonal allergies?

How the Dana

Menendez indictment could see pharma lose a key ally

leisure time

hotspot

explore

Continuity nursing helped my family in our darkest PICU moments

Medical experts exlpore how to eliminate bias in clinical algorithms

In Memoriam: Notable people who died in 2023

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Tori Bowie and the unacceptable rates of Black maternal death

FDA advisers vote against ALS treatment from BrainStorm

At least 13 dead in Texas as scorching temps continue

Mindstrong's demise and the future of mental health care

explore

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

After a drawn out lobbying fight, ARPA

Medical experts exlpore how to eliminate bias in clinical algorithms

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Medical experts exlpore how to eliminate bias in clinical algorithms

Wikipedia

focus

Wikipedia

leisure time